tiprankstipranks
Eiger BioPharmaceuticals CEO David Cory resigns, David Apelian named Interim CEO
The Fly

Eiger BioPharmaceuticals CEO David Cory resigns, David Apelian named Interim CEO

Eiger BioPharmaceuticals announced that David Cory has resigned as President, CEO and member of the Board of Directors, effective immediately.David Apelian, Senior Clinical Advisor and member of the Board of Directors, has been named as interim CEO and will also continue to serve on the company’s Board of Directors. The company plans to initiate an executive search to identify candidates to serve as a permanent CEO. Apelian has 23 years of clinical development and regulatory experience with large pharmaceutical and biotechnology companies, including nearly six years in senior management, advisory and Board roles at Eiger. He has been serving as a Director since 2017 and in 2018 was appointed COO and Executive Medical Officer.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on EIGR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles